SN-38-CO-DMEDA TFA

• CAT Number: I040947
• CAS Number: 1224601-17-5
• Molecular Formula: C29H31F3N4O8
• Molecular Weight: 620.57
• Purity: ≥95%
• Synonyms: [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] N-methyl-N-[2-(methylamino)ethyl]carbamate;2,2,2-trifluoroacetic acid
• InChI: InChI=1S/C27H30N4O6.C2HF3O2/c1-5-16-17-11-15(37-26(34)30(4)10-9-28-3)7-8-21(17)29-23-18(16)13-31-22(23)12-20-19(24(31)32)14-36-25(33)27(20,35)6-2;3-2(4,5)1(6)7/h7-8,11-12,28,35H,5-6,9-10,13-14H2,1-4H3;(H,6,7)/t27-;/m0./s1
• InChIKey: OPVMUGFXGHURAV-YCBFMBTMSA-N
• SMILES: CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)[C@@]4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N(C)CCNC.C(=O)(C(F)(F)F)O

SN-38-CO-DMEDA TFA(CAT: I040947) is a derivative of SN-38, the active metabolite of Irinotecan (CPT-11), a topoisomerase I inhibitor used in chemotherapy. SN-38 inhibits topoisomerase I, leading to DNA damage and apoptosis in rapidly dividing cancer cells. This compound is modified with DMEDA (N,N-Dimethylethylenediamine) and its trifluoroacetate (TFA) salt form may improve solubility or stability for research applications. Given its mechanism of action, SN-38-CO-DMEDA TFA is most relevant to Cancer Disease Research, particularly in studying drug modifications to enhance bioavailability, optimize pharmacokinetics, and improve anticancer efficacy in solid tumors like colorectal and lung cancers.